MarketPulse

vaccine development

7 articles
Investing.comInvesting.com··Tim Baker

Moderna Surges on Hantavirus Vaccine Success, Signaling mRNA Platform Diversification

Moderna stock rises after positive Phase 1 hantavirus vaccine data, with analysts raising price targets amid signs of mRNA platform diversification beyond COVID.
MRNAclinical trialpipeline expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion Consolidates Leadership, Promotes Rønø to Dual CSO-COO Role

Evaxion promotes Birgitte Rønø to combined Chief Scientific and Chief Operating Officer role to enhance platform communication and operational execution.
EVAXclinical-stageAI-Immunology platform
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bavarian Nordic Wins Swiss Approval for Chikungunya Vaccine VIMKUNYA

Bavarian Nordic secures Swiss regulatory approval for chikungunya vaccine VIMKUNYA, marking fourth major market clearance in 2025 following FDA, EMA, and MHRA approvals.
BVNRYregulatory milestonevaccine development
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion Unveils AI-Designed Polio Vaccines at World Congress, Backed by Gates Foundation

Evaxion presents AI-designed polio vaccine concepts at World Vaccine Congress, partnering with Gates Foundation to advance next-generation immunology platform.
EVAXAI-Immunology platformvaccine development
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

ELISpot & FluoroSpot Market Set for 7.1% Growth Through 2031

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.
MRKTMOBDXBIOBIO.B+1automationpersonalized medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Evaxion Schedules 2026 AGM as AI-Powered Vaccine Pipeline Advances

Danish biotech $EVAX announces April 2026 Annual General Meeting in Copenhagen while advancing AI-driven cancer and infectious disease vaccines.
EVAXAnnual General Meetingclinical pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Evaxion to Report 2025 Results, Showcase AI-Immunology Platform Progress

Danish biotech $EVAX will announce full-year 2025 financial results and business update March 5, detailing AI-Immunology platform development across oncology, infectious disease, and autoimmune applications.
EVAXfinancial resultsclinical-stage